AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AZN's COVID-19 vaccine received emergency use authorization in the U.K. AZN's Q3 revenue grew at 3% and EBITDA grew in the double-digit percentage range on cost-containment efforts.

AstraZeneca's COVID-19 Vaccine Could Be A Shot In The Arm

The United Kingdom on Wednesday become the first country to approve the coronavirus vaccine developed by Oxford University and AstraZeneca. The shot is cheaper and easier to distribute than alternatives, and is expected to play a crucial role in boosting the global economy next year.

Why the AstraZeneca vaccine is so important to the global economy

AstraZeneca's stock jumped on Wednesday after Britain authorized emergency use of the COVID-19 vaccine it developed with Oxford University.  The pharma group was among the FTSE 100's leaders as its shares jumped 0.7% in early European trading. Its shares were up about 3.3% at the start of trade.

AstraZeneca's stock jumps after the UK authorizes emergency use of its vaccine, which it created with Oxford University

Oxford Biomedica notes AstraZeneca's COVID-19 vaccine has been authorised for emergency supply in the UK

AstraZeneca plc (LON: AZN) said it received approval from the United Kingdom for its COVID-19 vaccine that it developed in collaboration with Oxford University on Wednesday. Britain is the 1st country to have approved the pharmaceutical giant's COVID-19 vaccine for use as it struggles to combat the pandemic that has so far infected more than 2.3 million people countrywide and caused over 71 thousand deaths.

Britain becomes the first country to approve AstraZeneca's COVID-19 vaccine

The Oxford University/AstraZeneca vaccinations will begin in early 2021.

Oxford COVID-19 vaccine approved for emergency use in UK

European markets traded just above flat on Wednesday, as the U.K. approved the AstraZeneca–Oxford University COVID-19 vaccine and prepared to push the post-Brexit trade deal through Parliament.

Europe Markets: European markets inch higher as U.K. approves AstraZeneca's COVID-19 vaccine

"We've got enough of this vaccine on order to vaccinate the whole population - 100 million doses," Health Secretary Matt Hancock said on Wednesday

U.K. now has enough vaccine “to cover the entire population” after AstraZeneca and Oxford COVID-19 vaccine approved

Following months of testing, a coronavirus vaccine created by Oxford-AstraZeneca has been authorized for emergency use by the United Kingdom. The vaccine was designed early on in the pandemic, and trials on it began in April. It's the second vaccine, after Pfizer BioNTech's, to be authorized in the UK. 

Oxford-AstraZeneca's COVID-19 vaccine has been authorized for emergency use in the UK

The COVID-19 vaccine co-developed by Oxford University and AstraZeneca plc (NASDAQ: AZN) received the United Kingdom approval for emergency supply on Wednesday.  What Happened: The U.K health department accepted the Medicines and Healthcare products Regulatory Agency (MHRA) recommendation to authorize AstraZeneca's COVID-19 vaccine, which showed efficacy between 70% and 90%.

AstraZeneca COVID-19 Vaccine Gets UK Nod For Emergency Use

AstraZeneca on Wednesday said the coronavirus vaccine it's developed with Oxford University has been approved by the U.K. government.

U.K. approves coronavirus vaccine AstraZeneca made with Oxford

The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has been authorized for emergency use in the U.K.

Oxford-AstraZeneca Covid vaccine approved by UK regulator 

The decision would pave the way for widespread vaccinations with a shot that is cheaper and easier to transport and store.

AstraZeneca and Oxford University's Covid-19 Vaccine Is Set for U.K. Approval

AstraZeneca (AZN) and partner Merck's Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.

AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers

Merck

The innovative treatment can now be used to help treat prostate, ovarian, and pancreatic cancer in the Asian country.

Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: AstraZeneca

The COVID-19 vaccine developed by AstraZeneca could receive emergency use authorization from UK regulators by Monday or Tuesday this week, with a rollout of the vaccine to UK citizens expected in the first week of 2021, according to The Telegraph.  AstraZeneca submitted its COVID-19 vaccine data to UK regulators on December 23, and CEO Pascal Soriot believes data will show the efficacy of its vaccine in preventing COVID-19 infections is as high as Pfizer & BioNtech's at 95%.

AstraZeneca jumps 6% after CEO says its COVID-19 vaccine will reach efficacy of 95% (AZN)

The coronavirus vaccine being developed by AstraZeneca and the University of Oxford will is expected to be approved for use in the U.K. in coming days.

UK expected to approve Oxford-AstraZeneca Covid vaccine this week

The United Kingdom could approve AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine as early as Tuesday, the Financial Times reports. What Happened: The U.K.'s Medicines and Healthcare products Regulatory Agency would give approval to the AstraZeneca-Oxford University vaccine imminently, government officials said Sunday, according to FT.

AstraZeneca COVID-19 Vaccine To Get UK Approval As Soon As Tuesday: FT

AstraZeneca's coronavirus vaccine is expected to be effective against mutating COVID-19 strains, including those discovered in the UK and South Africa.  "So far, we think the vaccine should remain effective," CEO Pascal Soriot told The Sunday Times. 

AstraZeneca's vaccine is expected to work on new COVID-19 strains, says CEO

Could AstraZeneca's COVID Vaccine Still Succeed?

Amgen

Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.

Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal

Approval of AstraZeneca-Oxford University shot would come as the U.K. grapples with a new coronavirus strain that has triggered a wave of travel bans.

AstraZeneca's COVID-19 vaccine could be approved in U.K. ‘shortly after Christmas' – top Oxford scientist says

The AstraZeneca vaccine is easier and cheaper to manufacture, store and transport.

U.K., India May Approve Cheaper Oxford-AstraZeneca Covid-19 Vaccine As Soon As Next Week

Compugen

HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under...

Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products

News for AstraZeneca Stock (AZN)